Study to Investigate Intravenous Blinatumomab in Japanese Adult Participants With Newly Diagnosed Philadelphia-negative B-precursor Acute Lymphoblastic Leukemia (B-ALL)
The main objective of the study is to evaluate safety and tolerability of blinatumomab in adult Japanese participants with newly diagnosed B-ALL.
B-precursor Acute Lymphoblastic Leukemia
DRUG: Blinatumomab
Number of Participants Experiencing Treatment-emergent Adverse Events (TEAEs), An adverse event (AE) is any untoward medical occurrence in a clinical study participant irrespective of a causal relationship with the study treatment. TEAEs are any event that occurred after the participant received study treatment. A serious AE (SAE) is defined as any untoward medical occurrence that is: immediately life-threatening, requires in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, a congenital anomaly/birth defect., Up to approximately 31 weeks|Number of Participants Experiencing Adverse Events of Interest (EOI), Up to 31 weeks
Steady-state Concentration (Css) of Blinatumomab, Day 1 pre-dose, 2 and 6 hours post-dose on Day 1, Day 2, Day 3, Day 29|Clearance (CL) of Blinatumomab, Day 1 pre-dose, 2 and 6 hours post-dose on Day 1, Day 2, Day 3, Day 29|Number of Participants Achieving Minimal Residual Disease (MRD) After Each Cycle of Blinatumomab, Cycles 1-4: Day 29 (each cycle is 6 weeks)|Number of Participants Achieving Hematologic Complete Remission (CR), Cycles 1-4: Day 29 (each cycle is 6 weeks)|Number of Participants Achieving Hematologic CR with Partial Peripheral Count Recovery (CRh), Cycles 1-4: Day 29 (each cycle is 6 weeks)
The main objective of the study is to evaluate safety and tolerability of blinatumomab in adult Japanese participants with newly diagnosed B-ALL.